Menu
  Home
Lab members
  • Armando Genazzani
  • Salvatore Terrazzino
  • Dmitry Lim
  • Ambra Grolla
  • Cristina Travelli
  • Sarah Cargnin
  • Simone Torretta
  • Beatrice Riva
  • Roberta Zaninetti
  • Francesca Rocchio
  •   Research
      Publications
      Contacts




    LAB MEMBERS
    Cristina Travelli
    Cristina Travelli


    Postdoc

    cristina.travelli@pharm.unipmn.it

    Areas of expertise:

    • NAD homeostasis
    • Cancer biology
       

    Background

    Nicotinamide adenine dinucleotide (NAD) is an essential coenzyme involved in numerous metabolic pathways, and it has been extensively demonstrated that a number of signaling pathways bring about its consumption. A rescue mechanism exists in cells to re-use nicotinamide released by NAD-metabolizing enzymes. This pathway, known as the "NAD salvage pathway"" is schematically composed of two enzymes: nicotinamide phosphoribosyl transferase (NAMPT; also known as visfatin or PBEF1) which forms nicotinamide mononucleotide (NMN) from nicotinamide and phosphoribosyl-pyrophosphate and nicotinamide mononucleotide adenylyl transferase (NMNAT) which leads to NAD from NMN and ATP.

    The link between NAMPT and cancer therapy is rapidly strengthening. NAMPT has been shown to be up-regulated in a number of solid tumours and has been postulated as a new target in cancer therapy. Two inhibitors of NAMPT (FK866 and CHS828) have been shown to have potent anti-tumoral activity in vitro and in vivo. It is now emerging that these agents may also be useful in inflammatory and autoimmune diseases, indeed NAMPT has been identified as a cytokine (eNAMPT) released by adipocytes and immune cells.

     

    Scientific Research

    My scientific interests are focused on studying the role of NAD metabolism in cancer biology. In particular, I'm interesting in characterize the role of NAMPT in cancer and to investigate the role of iNAMPT and eNAMPT in tumour progression and in tumour-related inflammation. We take advantage from FK866 to investigate both in vitro in different tumour cell lines and in vivo the role of NAMPT.

     

    Education

    2009-2012: PhD in Biotecnologie Farmaceutiche e Alimentari” at the Dipartimento di Scienze del Farmaco (DSF)

    2007-2009: 2-year degree in "Pharmaceutical and Medical Biotechnologies" (equivalent to a Master degree) at the University of Piemonte Orientale "A. Avogadro" (107/110)

    2004-2007: 3-year degree in Biotechnology at the University of Piemonte Orientale "A. Avogadro" (103/110)

     

    General Laboratory skills

    I have practical experience in techniques and skills in Molecular Biology, Cellular Biology and Cell Culture. I have also experience in working in a radioactive (32P) laboratory and experience in tumour mouse models.

    PUBLICATIONS
    10Extracellular Nicotinamide Phosphoribosyltrasferase (eNAMPT), A New Cancer Metabokine.
    Grolla AA(1), Travelli C(1), Genazzani AA(1), Sethi JK(1).
    Br J Pharmacol. 2016 Apr 29. doi: 10.1111/bph.13505. [Epub ahead of print]
    [Show abstract ]  
    9Triazole-curcuminoids: A new class of derivatives for 'tuning' curcumin bioactivities?
    Caprioglio D(1), Torretta S(1), Ferrari M(1), Travelli C(1), Grolla AA(1), Condorelli F(1), Genazzani AA(2), Minassi A(3).
    Bioorg Med Chem. 2016 Jan 15;24(2):140-52. doi: 10.1016/j.bmc.2015.11.044. Epub 2015 Nov 30.
    [Show abstract ]  
    8Nicotinamide phosphoribosyltransferase (NAMPT/PBEF/visfatin) is a tumoural cytokine released from melanoma.
    Grolla AA(1), Torretta S(1), Gnemmi I(1), Amoruso A(1), Orsomando G(2), Gatti M(1), Caldarelli A(1), Lim D(1), Penengo L(1,)(3), Brunelleschi S(1), Genazzani AA(1), Travelli C(1).
    Pigment Cell Melanoma Res. 2015 Sep 10. doi: 10.1111/pcmr.12420.
    [Show abstract ]  
    7Design, synthesis, and biological evaluation of combretabenzodiazepines: a novel class of anti-tubulin agents.
    Galli U(1), Travelli C, Aprile S, Arrigoni E, Torretta S, Grosa G, Massarotti A, Sorba G, Canonico PL, Genazzani AA, Tron GC.
    J Med Chem. 2015 Feb 12;58(3):1345-57. doi: 10.1021/jm5016389.
    [Show abstract ]  
    6Nicotinamide phosphoribosyltransferase (NAMPT) is over-expressed in melanoma lesions.
    Maldi E, Travelli C, Caldarelli A, Agazzone N, Cintura S, Galli U, Scatolini M, Ostano P, Miglino B, Chiorino G, Boldorini R, Genazzani A.
    Pigment Cell Melanoma Res. 2012 Oct 10. doi: 10.1111/pcmr.12037.
    [Show abstract ]  
    5The NAMPT inhibitor FK866 reverts the damage in spinal cord injury.
    Esposito E, Impellizzeri D, Mazzon E, Fakhfouri G, Rahimian R, Travelli C, Tron GC, Genazzani AA, Cuzzocrea S.
    J Neuroinflammation. 2012 Apr 10;9(1):66. [Epub ahead of print]
    [Show abstract ]  
    4Reciprocal potentiation of the antitumoral activities of FK866, an inhibitor of nicotinamide phosphoribosyltransferase, and etoposide or cisplatin in neuroblastoma cells.
    Travelli C, Drago V, Maldi E, Kaludercic N, Galli U, Boldorini R, Di Lisa F, Tron GC, Canonico PL, Genazzani AA.
    J Pharmacol Exp Ther. 2011 Jun 17.
    [Show abstract ]  
    3A novel potent nicotinamide phosphoribosyltransferase inhibitor synthesized via click chemistry.
    Colombano G, Travelli C, Galli U, Caldarelli A, Chini MG, Canonico PL, Sorba G, Bifulco G, Tron GC, Genazzani AA.
    J Med Chem. 2010 Jan 28;53(2):616-23.
    [Show abstract ]  
    2Characterization of NAD uptake in mammalian cells.
    Billington RA, Travelli C, Ercolano E, Galli U, Roman CB, Grolla AA, Canonico PL, Condorelli F, Genazzani AA.
    J Biol Chem. 2008 Mar 7;283(10):6367-74. Epub 2008 Jan 7.
    [Show abstract ]  
    1NAD depletion by FK866 induces autophagy.
    Billington RA, Genazzani AA, Travelli C, Condorelli F.
    Autophagy. 2008 Apr;4(3):385-7. Epub 2008 Jan 23.
    [Show abstract ]  

    Website maintained by Dmitry Lim